Search research articles
Contact Us
Filters
Showing results (71-80 of 138) with videos related to
Page
of 14
Sort By:
Gastroenterologie Clinique Et Biologique
|
March 29, 2008
Endoscopic ultrasonography is an independent predictive factor of prognosis in locally advanced esophageal cancer. Results from the randomized FFCD 9102 study from the Fédération Francophone de Cancérologie Digestive
P Burtin, O Bouché, M Giovannini, et al.
ESMO Gastrointestinal Oncology
|
February 6, 2026
Concomitant proton pump inhibitors and capecitabine-based chemoradiotherapy in rectal cancer: an ancillary study from the PRODIGE 23 trial
M Bridoux, E Aymes, T Conroy, et al.
Gastroenterologie Clinique Et Biologique
|
October 8, 1998
[Cisplatin, 5-FU and preoperative radiotherapy in esophageal epidermoid cancer. Multicenter phase II FFCD 8804 study]
L Bedenne, J F Seitz, C Milan, et al.
Bulletin Du Cancer
|
September 4, 2008
[Systematic review: value of perioperative chemotherapy in the management of resectable rectal adenocarcinoma (brief report)]
Y Bécouarn, S Guillo, P Artru, et al.
Revue D'Epidemiologie Et De Sante Publique
|
December 6, 2005
[Cancer patient's satisfaction assessment using the EORTC QLQ-SAT32: comparison between self-assessment and interview response]
A Brédart, V Mignot, A Rousseau, et al.
Patient Education and Counseling
|
August 4, 2004
Validation of the EORTC QLQ-SAT32 cancer inpatient satisfaction questionnaire by self- versus interview-assessment comparison
A Brédart, V Mignot, A Rousseau, et al.
Bulletin Du Cancer
|
March 1, 1993
[Combination of 5-FU, high dose methotrexate, epirubicin and cisplatin (FEMTX-P protocol) in non surgical or locally recurrent metastatic gastric cancers]
T Conroy, J Wils, B Paillot, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 4, 2001
Development of an EORTC disease-specific quality of life module for use in patients with gastric cancer
C W Vickery, J M Blazeby, T Conroy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 1, 1993
Phase II study of sequential high-dose methotrexate (MTX) and 5-fluorouracil (F) alternated with epirubicin (E) and cisplatin (P) [FEMTX-P] in advanced gastric cancer
E J Roelofs, D J Wagener, T Conroy, et al.
American Journal of Clinical Oncology
|
April 1, 1994
Acute antiemetic efficacy and safety of dolasetron mesylate, a 5-HT3 antagonist, in cancer patients treated with cisplatin. European Dolasetron Study Group
T Conroy, P Cappelaere, M Fabbro, et al.
Page
of 14
Search research articles
Search
Showing results (71-80 of 138) with videos related to
Sort By:
Page
of 14
Gastroenterologie Clinique Et Biologique
|
March 29, 2008
Endoscopic ultrasonography is an independent predictive factor of prognosis in locally advanced esophageal cancer. Results from the randomized FFCD 9102 study from the Fédération Francophone de Cancérologie Digestive
P Burtin, O Bouché, M Giovannini, et al.
ESMO Gastrointestinal Oncology
|
February 6, 2026
Concomitant proton pump inhibitors and capecitabine-based chemoradiotherapy in rectal cancer: an ancillary study from the PRODIGE 23 trial
M Bridoux, E Aymes, T Conroy, et al.
Gastroenterologie Clinique Et Biologique
|
October 8, 1998
[Cisplatin, 5-FU and preoperative radiotherapy in esophageal epidermoid cancer. Multicenter phase II FFCD 8804 study]
L Bedenne, J F Seitz, C Milan, et al.
Bulletin Du Cancer
|
September 4, 2008
[Systematic review: value of perioperative chemotherapy in the management of resectable rectal adenocarcinoma (brief report)]
Y Bécouarn, S Guillo, P Artru, et al.
Revue D'Epidemiologie Et De Sante Publique
|
December 6, 2005
[Cancer patient's satisfaction assessment using the EORTC QLQ-SAT32: comparison between self-assessment and interview response]
A Brédart, V Mignot, A Rousseau, et al.
Patient Education and Counseling
|
August 4, 2004
Validation of the EORTC QLQ-SAT32 cancer inpatient satisfaction questionnaire by self- versus interview-assessment comparison
A Brédart, V Mignot, A Rousseau, et al.
Bulletin Du Cancer
|
March 1, 1993
[Combination of 5-FU, high dose methotrexate, epirubicin and cisplatin (FEMTX-P protocol) in non surgical or locally recurrent metastatic gastric cancers]
T Conroy, J Wils, B Paillot, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 4, 2001
Development of an EORTC disease-specific quality of life module for use in patients with gastric cancer
C W Vickery, J M Blazeby, T Conroy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 1, 1993
Phase II study of sequential high-dose methotrexate (MTX) and 5-fluorouracil (F) alternated with epirubicin (E) and cisplatin (P) [FEMTX-P] in advanced gastric cancer
E J Roelofs, D J Wagener, T Conroy, et al.
American Journal of Clinical Oncology
|
April 1, 1994
Acute antiemetic efficacy and safety of dolasetron mesylate, a 5-HT3 antagonist, in cancer patients treated with cisplatin. European Dolasetron Study Group
T Conroy, P Cappelaere, M Fabbro, et al.
Page
of 14